UBS Raises Default Rate Forecast Amid Economic Concerns
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 26 2025
0mins
Should l Buy UBS?
Source: Coinmarketcap
UBS Group AG's stock has fallen significantly, hitting a 20-day low amid broader market declines, with the Nasdaq-100 down 2.26% and the S&P 500 down 2.17%.
The decline follows UBS's warning of rising default rates in private credit, now forecasted at 15%, reflecting increased concerns about disruptions from artificial intelligence affecting corporate borrowers. This news has heightened investor anxiety, contributing to the stock's drop as the market reacts to fears of economic instability and potential impacts on credit liquidity.
The implications of UBS's revised forecast suggest a challenging environment for private credit markets, particularly for technology sector borrowers, which may lead to further volatility in stock prices as investors reassess risk exposure.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UBS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UBS
Wall Street analysts forecast UBS stock price to rise
11 Analyst Rating
7 Buy
2 Hold
2 Sell
Moderate Buy
Current: 36.410
Low
39.12
Averages
52.09
High
71.73
Current: 36.410
Low
39.12
Averages
52.09
High
71.73
About UBS
UBS Group AG is a Switzerland-based holding company and conducts its operations through UBS AG and its subsidiaries. The company operates as a wealth manager with focused asset management and investment banking capabilities and a capital-light and cash-generative business model. The Company comprises four business divisions: Global Wealth Management, which provides tailored advice and solutions to its clients around the globe; Personal & Corporate Banking division provides comprehensive financial products and services to private, corporate and institutional clients in Switzerland; Asset Management division offers investment capabilities and styles across all traditional and alternative asset classes, as well as advisory support to institutions; Investment Bank provides investment advice, financial solutions and capital markets access to institutional, corporate and wealth management clients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
UBS Announces 53 Advisors Named to 2026 Barron's Top 1500 List
- Advisor Recognition: UBS has announced that 53 financial advisors from its Southeast region have been named to the 2026 Barron's Top 1500 Financial Advisors list, highlighting the firm's excellence and recognition in wealth management.
- Leadership Endorsement: Regional Director Julie Fox emphasized that the expertise and care these advisors provide to clients set them apart, further enhancing UBS's brand image in the competitive financial services landscape.
- Rigorous Selection Criteria: The Barron's list is compiled based on various criteria, including revenue generated for the firm, assets under management, quality of practice, and regulatory record, ensuring the list's authority and fairness.
- Global Wealth Management Leader: As a leading global wealth manager, UBS manages $6.1 trillion in invested assets and remains committed to helping clients achieve their financial goals through personalized advice and solutions.
See More
UBS Initiates Neutral Coverage on Jasper Therapeutics with $1.50 Target
- Coverage Initiation: UBS initiated coverage of Jasper Therapeutics (NASDAQ:JSPR) on March 23, 2026, with a Neutral rating and a $1.50 price target, indicating a cautious outlook due to competitive pressures that may limit upside potential.
- Clinical Data Update: On January 8, 2026, Jasper reported updated data for briquilimab, revealing that 67% of patients achieved a complete response at 12 weeks, while 83% responded by week 3 after the initial dose, highlighting the therapy's promise in chronic spontaneous urticaria (CSU).
- Future Research Plans: The company plans to initiate a Phase 2b study for CSU in the second half of 2026, with BEACON and open-label extension data supporting dose selection, demonstrating positive progress in clinical development.
- Investment Outlook Analysis: While Jasper is viewed as a potential investment, UBS noted that certain AI stocks offer greater upside potential and lower downside risk, reflecting a shift in market preference towards more attractive investment options in the biotech sector.
See More
European Economy Faces Energy-Driven Inflation Challenges
- Energy-Driven Inflation Pressure: The war with Iran has intensified macro uncertainty, leading UBS to predict that Europe will face new energy-driven inflation, with consumer prices remaining elevated and real incomes under pressure, despite a full-scale recession not being the base case.
- Risk of Growth Slowdown: Analysts warn that the duration of current maritime disruptions will determine whether Europe faces a shallow slowdown or deeper stagnation, with GDP growth expected to modestly slow as private consumption and corporate investment are deferred.
- Urgency of Policy Response: A prolonged closure of the Strait of Hormuz would likely push inflation significantly higher, forcing central banks to maintain a restrictive policy stance longer than anticipated, which will compress margins for debt-heavy sectors and energy-intensive manufacturing.
- Strategic Investor Adjustments: UBS advises institutional investors to adopt selective de-risking strategies in the uncertain environment, focusing on
See More
Apple's Stock Struggles in 2023: Analysts Predict a Brighter Future.
- Stock Performance: Apple stock has faced challenges this year, marked by a series of four consecutive weekly declines.
- Analyst Optimism: Recent analyst reports highlight strong iPhone loyalty and the upcoming release of a new MacBook as positive indicators for the company's future.
See More
Microsoft Shares Experience Worst Six-Month Performance Since 2009
- Stock Performance: Microsoft stock is experiencing its worst six-month performance since 2009.
- Year Start: The company is facing its worst start to a year ever.
See More
Microsoft Shares Experience Worst Six-Month Period Since 2009
- Stock Performance: Microsoft stock is experiencing its worst six-month performance since 2009.
- Year Start: The company is facing its worst start to a year ever.
See More
UBS Announces 53 Advisors Named to 2026 Barron's Top 1500 List
- Advisor Recognition: UBS has announced that 53 financial advisors from its Southeast region have been named to the 2026 Barron's Top 1500 Financial Advisors list, highlighting the firm's excellence and recognition in wealth management.
- Leadership Endorsement: Regional Director Julie Fox emphasized that the expertise and care these advisors provide to clients set them apart, further enhancing UBS's brand image in the competitive financial services landscape.
- Rigorous Selection Criteria: The Barron's list is compiled based on various criteria, including revenue generated for the firm, assets under management, quality of practice, and regulatory record, ensuring the list's authority and fairness.
- Global Wealth Management Leader: As a leading global wealth manager, UBS manages $6.1 trillion in invested assets and remains committed to helping clients achieve their financial goals through personalized advice and solutions.
See More
UBS Initiates Neutral Coverage on Jasper Therapeutics with $1.50 Target
- Coverage Initiation: UBS initiated coverage of Jasper Therapeutics (NASDAQ:JSPR) on March 23, 2026, with a Neutral rating and a $1.50 price target, indicating a cautious outlook due to competitive pressures that may limit upside potential.
- Clinical Data Update: On January 8, 2026, Jasper reported updated data for briquilimab, revealing that 67% of patients achieved a complete response at 12 weeks, while 83% responded by week 3 after the initial dose, highlighting the therapy's promise in chronic spontaneous urticaria (CSU).
- Future Research Plans: The company plans to initiate a Phase 2b study for CSU in the second half of 2026, with BEACON and open-label extension data supporting dose selection, demonstrating positive progress in clinical development.
- Investment Outlook Analysis: While Jasper is viewed as a potential investment, UBS noted that certain AI stocks offer greater upside potential and lower downside risk, reflecting a shift in market preference towards more attractive investment options in the biotech sector.
See More
European Economy Faces Energy-Driven Inflation Challenges
- Energy-Driven Inflation Pressure: The war with Iran has intensified macro uncertainty, leading UBS to predict that Europe will face new energy-driven inflation, with consumer prices remaining elevated and real incomes under pressure, despite a full-scale recession not being the base case.
- Risk of Growth Slowdown: Analysts warn that the duration of current maritime disruptions will determine whether Europe faces a shallow slowdown or deeper stagnation, with GDP growth expected to modestly slow as private consumption and corporate investment are deferred.
- Urgency of Policy Response: A prolonged closure of the Strait of Hormuz would likely push inflation significantly higher, forcing central banks to maintain a restrictive policy stance longer than anticipated, which will compress margins for debt-heavy sectors and energy-intensive manufacturing.
- Strategic Investor Adjustments: UBS advises institutional investors to adopt selective de-risking strategies in the uncertain environment, focusing on
See More
Apple's Stock Struggles in 2023: Analysts Predict a Brighter Future.
- Stock Performance: Apple stock has faced challenges this year, marked by a series of four consecutive weekly declines.
- Analyst Optimism: Recent analyst reports highlight strong iPhone loyalty and the upcoming release of a new MacBook as positive indicators for the company's future.
See More
Microsoft Shares Experience Worst Six-Month Performance Since 2009
- Stock Performance: Microsoft stock is experiencing its worst six-month performance since 2009.
- Year Start: The company is facing its worst start to a year ever.
See More
Microsoft Shares Experience Worst Six-Month Period Since 2009
- Stock Performance: Microsoft stock is experiencing its worst six-month performance since 2009.
- Year Start: The company is facing its worst start to a year ever.
See More
